

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	(Use as many sneets as necessary)						
Sheet	1	of	7				

Complete if Known					
Application Number	10/682,332				
Filing Date	October 8, 2003				
First Named Inventor	David L. SHELTON				
Art Unit	1647				
Examiner Name	J. Lockard				
Attorney Docket Number	514712000600				

	U.S. PATENT DOCUMENTS						
Exam Initials		Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
JL		1.	US-2002/0072543-A1	06-13-2002	Olesen et al.		
		2.	US-2002/0146416-A1	10-10-2002	Presta et al.		
		3.	US-2003/0008807-A1	01-09-2003	Levine et al.		
		4.	US-2003/0072746-A1	04-17-2003	Miller	·	
		5.	US-2003/0203923-A1	10-30-2003	Ross et al.		
		6.	US-2004/0038874-A1	02-26-2004	Omoigui		
		7.	US-2004/0071701-A1	04-15-2004	Delafoy et al.		
		8.	US-2004/0097562-A1	05-20-2004	Olesen et al.		
		9.	US-2004/0121959-A1	06-24-2004	Boone et al.		
		10.	US-2005/0074821-A1	04-07-2005	Wild, Jr. et al.		
		11.	US-2005/0222035-A1	10-06-2005	Boone et al.		
		12.	US-2005/0265994-A1	12-01-2005	Shelton et al.		
		13.	US-RE 38,103-E	04-29-2003	Guay et al.		
		14.	US-5,656,435-A	08-12-1997	Nakahama et al.		
		15.	US-5,712,100-A	01-27-1998	Nakahama et al.	·	
		16.	US-6,022,875-A	02-08-2000	Zimmer et al.		
		17	US-6,027,927-A	02-22-2000	Presta et al.		
		18.	US-6,399,780-B1	06-04-2002	Hudkins		
		19.	US-6,492,380-B1	12-10-2002	Ross et al.		
		20.	US-6,548,062-B2	04-15-2003	Buchkovich et al.		
\Box	/	21.	US-6,548,640-B1	04-15-2003	Winter		
V	/	22.	US-6,649,605-B2	11-18-2003	Olesen et al.		
J	L	23.	US-6,919,426-B2	07-19-2005	Boone et al.	·	

		FOREI	GN PATENT	DOCUMENTS	·	
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No.1	No. 1 Country Code3-Number4-Kind Code3 (if known)		Applicant of Cited Document	or Relevant Figures Appear	T ⁰
JL	24.	EP-0 418 590-A1, B1	03-27-1991	Takeda Chemical Industries, Ltd.		
	25.	FR-2 807 660-A1	10-19-2001	Warner Lambert Co.	Translation of Abstract Only	
	26.	JP 03-163095-A	07-15-1991	Takeda Chemical Industries Ltd.	Translation of Abstract Only	
	27.	JP 05-076384-A	03-30-1993	Hitachi Ltd.	Translation of Abstract Only	
	28.	JP 06-317587-A	11-15-1994	Takeda Chemical Industries Ltd.	Translation of Abstract Only	
	29.	JP-63-295588-A	12-01-1988	Kyowa Hakko Kogyo KK	Translation of Abstract Only	
	30.	WO-90/10644-A1	09-20-1990	Lope Medicine AB		
	31.	WO-95/25795-A1	09-28-1995	Genentech, Inc.	••	
	32.	WO-98/19674-A2, A3	05-14-1998	Olesen et al.		
	33.	WO-01/52843-A1	07-26-2001	McGill University et al.		
V	34.	WO-02/20513-A1	03-14-2002	Glaxo Group Limited		
JL	35.	WO-02/102232-A2, A3	12-27-2002	The Regents of the University of California		

Examiner /Jon Lockard/	Date Considered	01/04/2007

		70		Complete if Known		
Substitu	te for form 1449/P	10		Application Number	10/682,332	
INF	ORMATI	ON DISC	CLOSURE	Filing Date	October 8, 2003	
			PLICANT	First Named Inventor	David L. SHELTON	
017		וטואו	LIOAITI	Art Unit	1647	
	(Use as man	y sheets as ne	cessary)	Examiner Name	J. Lockard	
Sheet	Sheet 2 of 7		Attorney Docket Number	514712000600		

JL	36.	WO-03/022261-A1	03-20-2003	Miller	
	37.	WO-2004/026329-A1	04-01-2004	Amgen, Inc.	
	38.	WO-2004/028448-A2, A3	04-08-2004	Miller	
	/ 39	WO-2004/032852-A2, A3	04-22-2004	Rinat Neurosciences Corp.	
	40.	WO-2005/019266-A2, A3	03-03-2005	Amgen, Inc.	
JI	41.	WO-2005/111077-A2, A3	11-24-2005	Rinat Neuroscience Corp. et	
ا ا	'			al.	

"EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	io. magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, and/or country where published.			
ĴĹ	42. Abbadie, C. et al. (June 24, 2003). "Impaired Neuropathic Pain Responses in Mice Chemokine Receptor CCR2," <i>Proc. Natl. Acad. Sci. USA</i> 100(13):7947-7952.				
	43.	Aloe, L. et al. (1993). "The Synovium of Transgenic Arthritic Mice Expressing Human Tumor Necrosis Factor Contains a High Level of Nerve Growth Factor," <i>Growth Factors</i> 9(2):149-155.			
	44.	Aloe, L. et al. (SeptOct. 1999). "Nerve Growth Factor in the Synovia of Patients with Rheumatoid Arthritis: Correlation with TNF-α and IL-1β and Possible Functional Significance." Clin. Exp. Rheumatol. 17(5):632-633.			
	 Altschul, S.F. et al. (1997). "Gapped BLAST and PSI-BLAST: A New Generation of Production of Production Production of Production P				
	46.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34237CS, column 3, lines 5-7.			
	47.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34237CS, column 3, lines 55-60.			
	48.	American Chemical Society (1987-1991). Chemical Abstracts. 12th Collective Index, Chemical Substances, Volumes 106-115, page 34237CS, column 3, lines 66-69.			
	49.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34238CS, column 1, lines 41-44.			
	50.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34238CS, column 2, lines 25-27.			
	51.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34238CS, column 2, lines 32-33.			
	52.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34239CS, column 3, lines 48-50.			
	53.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34239CS, column 3, lines 52-53.			
	54.	Barbas III, C.F. et al. (April 1994). "In vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity," Proc. Natl. Acad. Sci. USA 91:3809-3813.			
	55.	Barbas III, C.F. et al. (2001). "Vector pComb3X, Figure 2.2" In "Phage-Display Vectors" Chapter 2 In Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, pp. 2.9-2.13.			
JL	56.	Barkin, R.L. (2001). "Acetaminophen, Aspirin, or Ibuprofen in Combination Analgesic Products," <i>American Journal of Therapeutics</i> 8(6):433-442.			

Examiner /Jon Loc	kard/	Date Considered	01/04/2007
14411-1			

9	ostitute for form 1449/PTC	`	,	Complete If Known		
300	334446 101 101111 144 37 7 1	,		Application Number	10/682,332	
11	NFORMATIO	N DI	SCLOSURE	Filing Date	October 8, 2003	
S	TATEMENT	BY	APPLICANT	First Named Inventor	David L. SHELTON	
				Art Unit	1647	
	(Use as many s	sheets as	necessary)	Examiner Name	J. Lockard	
Sheet	eet . 3 of 7		Attorney Docket Number	514712000600		

JL	57.	Bellamy, N. (May 1989). "Pain Assessment in Osteoarthritis: Experience With the WOMAC Osteoarthritis Index," Semin. Arthritis Rheum. 18(4 Suppl. 2):14-17.
	58.	Bellamy, N. et al. (December 1988). "Validation Study of WOMAC: A Health Status Instrument for Measuring Clinically Important Patient Relevant Outcomes to Antirheumatic Drug Therapy in Patients with Osteoarthritis of the Hip or Knee," J. Rheumatol. 15(12):1833-1840.
	59.	Bibel, M. et al. (December 1, 2000). "Neurotrophins: Key Regulators of Cell Fate and Cell Shape in the Vertebrate Nervous System," Genes Dev. 14(23):2919-2937.
	60.	Brennan, T.J. (1999). "Postoperative Models of Nociception," ILAR Journal 40(3):129-136.
	61.	Brosseau, L. et al. (2003). "Thermotherapy for Treatment of Osteoarthritis," The Cochrane Database of Systematic Reviews Issue 4, Art No. CD004522, pp. 1-20.
	62.	Chaplan, S.R. et al. (1994). "Quantitative Assessment of Tactile Allodynia in the Rat Paw," J. Neuroscience Methods 53:55-63.
	63.	Chen, Y. et al. (November 5, 1999). "Selection and Analysis of an Optimized Anti-VEGF Antibody. Crystal Structure of an Affinity-Matured Fab in Complex with Antigen," <i>J. Mol. Biol.</i> 293(4):865-881.
	64.	Choi, S-S. et al. (2003). "Antinociceptive Mechanisms of Orally Administered Decursinol in the Mouse," <i>Life Sciences</i> 73(4):471-485.
·	65.	Clohisy, D.R. et al. (2003). "Skeletal Complications of Malignancy: Bone Cancer Pain," Clinical Orthopaedics and Related Research 415S:S279-S288.
	66.	Corey, E. et al. (June 1, 2002). "Establishment and Characterization of Osseous Prostate Cancer Models: Intra-Tibial Injection of Human Prostate Cancer Cells," <i>Prostate</i> 52(1):20-33.
	67.	Cromartie, W.J. et al. (1977). "Arthritis in Rats After Systemic Injection of Streptococcal Cells or Cell Walls," <i>The Journal of Experimental Medicine</i> 146:1585-1602.
	68.	Dicou, E. et al. (September 1993). "Natural Autoantibodies Against the Nerve Growth Factor in Autoimmune Diseases," <i>J. Neuroimmunol.</i> 47(2):159-167.
	69.	Dicou, E. et al. (December 13, 1993). "Increased Frequency of NGF in sera of Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients," NeuroReport 5(3):321-324.
	70.	Dicou, E. et al. (January 1994). "Natural Autoantibodies Against the Nerve Growth Factor in Autoimmune Diseases," <i>J. Neuroimmunol.</i> 49(1):224 (Erratum).
	71.	Dicou, E. et al. (1996). "Nerve Growth Factor (NGF) Autoantibodies and NGF in the Synovial Fluid: Implications in Spondylarthropathies," <i>Autoimmunity</i> 24(1):1-9.
	72.	Dicou, E. et al. (May 1997). "Evidence That Natural Autoantibodies Against the Nerve Growth Factor (NGF) May Be Potential Carriers of NGF," J. Neuroimmunol. 75:200-203.
	73.	Edoff, K. et al. (February 2000). "Retrograde Tracing and Neuropeptide Immunohistochemistry of Sensory Neurones Projecting to the Cartilaginous Distal Femoral Epiphysis of Young Rats," Cell & Tissue Research 299(2):193-200.
	74.	Fawcett, D.W. (1986). "Bone" Chapter 8 In A Textbook of Histology, Dreibelbis, D. ed., Eleventh Edition, W.B. Saunders Co.: Philadelphia, PA, pp. 211-216 and Table of Contents pp. v-xi.
	75.	Fischer, H.P. et al. (June 1998). "A Possible Role for Saliva as a Diagnostic Fluid in Patients with Chronic Pain," Semin. Arthritis Rheum. 27(6):348-359.
	76.	Fjell, J. et al. (February 1999). "In Vivo NGF Deprivation Reduces SNS Expression and TTX-R Sodium Currents in IB4-Negative DRG Neurons," J. Neurophysiol. 81(2):803-810.
	77.	García-Castellano, J.M. et al. (2000). "Is Bone a Target-Tissue for the Nervous System? New Advances on the Understanding of Their Interactions," <i>Jowa Orthop. J.</i> 20:49-58.
	78.	Garrett, N.E. et al. (July 11, 1997). "Effect of Capsaicin on Substance P and Nerve Growth Factor in Adjuvant Arthritic Rats," Neurosci. Lett. 230:5-8.
V	79.	Gavilondo, J.V. et al. (July 2000). "Antibody Engineering at the Millennium," <i>BioTechniques</i> 29:128-145.
JL	80.	GenBank Accession No. CAA09181, created December 2, 1998, located at http://www.ncbi.nlm.nih.gov , last visited October 19, 2005, two pages.

l Examiner I	/ Tan Tanland /	Date	
	/Jon Lockard/	· · ·	01/04/2007
Signature	· · · · · · · · · · · · · · · · · · ·	Considered	01/04/2007
		00.10/00.00	
DO 1004474			

Sul	estitute for form 1449/PTC	<u> </u>		Complete if Known		
04.	3	•		Application Number	10/682,332	
11	NFORMATIC	N DIS	CLOSURE	Filing Date	October 8, 2003	
	TATEMENT	_		First Named Inventor	David L. SHELTON	
				Art Unit	1647	
	(Use as many sheets as necessary)			Examiner Name	J. Lockard	
Sheet	4	of	7	Attorney Docket Number	514712000600	

JL	81.	GenBank Accession No. P01859, created July 21, 1986, located at http://www.ncbi.nlm.nih.gov , last visited October 19, 2005, four pages.	
	82.	Greene, L.A. et al. (July 1976). "Establishment of a Noradrenergic Clonal Line of Rat Adrenal Pheochromocytoma Cells Which Respond to Nerve Growth Factor," <i>Proc. Nat. Acad. Sci. USA</i>	·
	83.	73(7):2424-2428. Halliday, D.A. et al. (June 1998). "Elevated Nerve Growth Factor Levels in the Synovial Fluid of Patients With Inflammatory Joint Disease," <i>Neurochem. Res.</i> 23(6):919-922.	_
	84.	Hasselström, J. et al. (July 1996). "Disposition and Analgesic Effects of Systemic Morphine, Morphine-6-glucuronide and Normorphine in Rat," <i>Pharmacology & Toxicology</i> 79(1):40-46.	
	85.	Haynes, M.K. et al. (December 2002). "Phenotypic Characterization of Inflammatory Cells From Osteoarthritic Synovium and Synovial Fluids," Clin. Immunol. 105(3):315-325.	
	86.	Hill, R. (July 2000). "NK ₁ (Substance P) Receptor Antagonists - Why Are They Not Analgesic in Humans?" <i>Trends Pharmacol. Sci.</i> 21(7):244-246.	
	87.	Honoré, P. et al. (2000). "Cellular and Neurochemical Remodeling of the Spinal Cord in Bone Cancer Pain," <i>Prog. Brain Res.</i> 129:389-397.	
	88.	Honoré, P. et al. (May 2000). "Osteoprotegerin Blocks Bone Cancer-Induced Skeletal Destruction, Skeletal Pain and Pain-Related Neurochemical Reorganization of the Spinal Cord," Nat. Med. 6(5):521-528.	
	89.	Honoré, P. et al. (June 23, 2000). "Murine Models of Inflammatory, Neuropathic and Cancer Pain Each Generates a Unique Set of Neurochemical Changes in the Spinal Cord and Sensory Neurons," Neuroscience 98(3):585-598.	
	90.	Huang, E.J. et al. (2001). "Neurotrophins: Roles in Neuronal Development and Function," Annu. Rev. Neurosci. 24:677-736.	
	91.	Hunt, S.P. et al. (August 13, 1987). "Induction of c-fos-like Protein in Spinal Cord Neurons Following Sensory Stimulation," <i>Nature</i> 328:632-634.	
	92.	Huse, W.D. et al. (1993). "Increased Antibody Affinity and Specificity by Codon-Based Mutagenesis," <i>Intern. Rev. Immunol.</i> 10:129-137.	
	93.	ladarola, M.J. et al. (1988). "Differential Activation of Spinal Cord Dynorphin and Enkephalin Neurons During Hyperalgesia: Evidence Using cDNA Hybridization," <i>Brain Res.</i> 455(2):205-212.	
	94.	International Search Report for PCT Application No. PCT/US03/32113, filed October 8, 2003, mailed April 10, 2006, four pages.	
	95.	International Search Report for PCT Application No. PCT/US04/05162 filed February 19, 2004, mailed March 28, 2006, four pages.	
	96.	International Search Report for PCT Application No. PCT/US2005/011786, filed April 7, 2005, mailed February 20, 2006, five pages.	
	97.	Jongen, J.L.M. et al. (2002). "Neurotrophic Factors and Cancer Pain: The Expression of NGF, GDNF and BDNF by the Murine Osteolytic Sarcoma Cell Line 2472 in vitro and in vivo and Their Potential Involvement in Bone Cancer Pain," 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL, (November 2-7, 2002), Abstract 52.2, located at http://sfn.scholarone.com/iten2002/main.html , last visited March 2, 2006, two pages.	
	98.	Kasai, M. et al. (1999). "Endogenous Nerve Growth Factor Increases the Sensitivity to Bradykinin in Small Dorsal Root Ganglion Neurons of Adjuvant Inflamed Rats," <i>Neuroscience Letters</i> 272(1):41-44.	
	99.	Kazemier, B. et al. (1996). "Determination of Active Single Chain Antibody Concentrations in Crude Periplasmic Fractions," <i>J. Immunol. Methods</i> 194(2):201-209.	
	100.	Lewin, G.R. et al. (May 1993). "Nerve Growth Factor-Induced Hyperalgesia in the Neonatal and Adult Rat," <i>J. Neurosci.</i> 13(5):2136-2148.	
V	101.	Luger, N.M. et al. (May 15, 2001). "Osteoprotegerin Diminishes Advanced Bone Cancer Pain," Cancer Res. 61:4038-4047.	
JL	102.	Luger, N.M. et al. (2002). "Efficacy of Systemic Morphine Suggests a Fundamental Difference in the Mechanisms that Generate Bone Cancer vs. Inflammatory Pain," Pain 99:397-406.	

Signature /Jon Lockard/ Date Considered 01/04/2007		ire /Jon Lockard/	Date Considered 01/04/2007	
--	--	-------------------	-------------------------------	--

Sub	estitute for form 1449/PTC	`		Complete if Known		
Jul				Application Number	10/682,332	
IN	NFORMATIC	N DIS	SCLOSURE	Filing Date	October 8, 2003	
	TATEMENT			First Named Inventor	David L. SHELTON	
				Art Unit	1647	
	(Use as many sheets as necessary)			Examiner Name	J. Lockard	
Sheet	5	of	7	Attorney Docket Number	514712000600	

J	L.	103.	Mach, D.B. et al. (2002). "Origins of Skeletal Pain: Sensory and Sympathetic Innervation of the Mouse Femur," <i>Neuroscience</i> 113(1):155-166.
	Γ	104.	Mantyh, P.W. et al. (March 2002). "Molecular Mechanisms of Cancer Pain," Nature Reviews Cancer 2(3):201-209.
		105.	McCarthy, B.G. et al. (October 1995). "Cutaneous Innervation in Sensory Neuropathies," Neurology 45(10):1848-1855.
		106.	McDonald, N.Q. et al. (December 5, 1991). "New Protein Fold Revealed by a 2.3-A Resolution Crystal Structure of Nerve Growth Factor," <i>Nature</i> 354:411-414.
		107.	McMahon, S.B. (August 1995). "The Biological Effects of Endogenous Nerve Growth Factor on Adult Sensory Neurons Revealed by a trkA-IgG Fusion Molecule," <i>Nature Medicine</i> 1(8):774-780.
		108.	McMahon, S.B. (March 29, 1996). "NGF as a Mediator of Inflammatory Pain," Phil. Trans. R. Soc. Land. B 351(1338):431-440.
		109.	Molander, C. et al. (June 8, 1987). "Spinal Cord Projections From Hindlimb Muscle Nerves in the Rat Studied by Transganglionic Transport of Horseradish Peroxidase, Wheat Germ-Agglutinin Conjugated Horseradish Peroxidase, or Horseradish Peroxidase With Dimethylsulfoxide," J. Comp. Neurol. 260(2):246-255.
		110.	Muller, Y.A. et al. (1998). "VEGF and the Fab Fragment of a Humanized Neutralizing Antibody: Crystal Structure of the Complex at 2.4 Å Resolution and Mutational Analysis of the Interface," Structure 6(9):1153-1167.
		111.	Muyldermans, S. (2001). "Single Domain Camel Antibodies: Current Status," Reviews in Molecular Biotechnology 74:277-302.
		112.	Myers, R.R. et al. (September 1996). "Reduced Hyperalgesia in Nerve-Injured WLD Mice: Relationship to Nerve Fiber Phagocytosis, Axonal Degeneration, and Regeneration in Normal Mice," Exp. Neurol. 141(1):94-101.
		113.	Niissalo, S. et al. (June 2002). "Neuropeptides in Experimental and Degenerative Arthritis," Ann. N.Y. Acad. Sci. 966:384-399.
		114.	Noguchi, K. et al. (1991). "Dynorphin Expression and Fos-like Immunoreactivity Following Inflammation Induced Hyperalgesia are Colocalized in Spinal Cord Neurons," <i>Molecular Brain Research</i> 10(3):227-233.
		115.	Peter, E.A. et al. (October 30, 2001). "Ibuprofen Versus Acetaminophen with Codeine for the Relief of Perineal Pain after Childbirth: A Randomized Controlled Trial," CMAJ 165(9):1203-1209.
		116.	Pezet, S. et al. (February 1, 2001). "Differential Regulation of NGF Receptors in Primary Sensory Neurons by Adjuvant-Induced Arthritis in the Rat," Pain 90(1-2):113-125.
		117.	Pozza, M. et al. (May 2000). "A Histochemical Study of the Rheumatoid Synovium: Focus on Nitric Oxide, Nerve Growth Factor High Affinity Receptor, and Innervation," <i>J. Rheumatol.</i> 27(5):1121-1127.
		118.	Puigdellivol-Sánchez, A. et al. (1998). "Sciatic and Femoral Nerve Sensory Neurones Occupy Different Regions of the L4 Dorsal Root Ganglion in the Adult Rat," <i>Neurosci. Lett.</i> 251(3):169-172.
		119.	Puigdellivol-Sánchez, A. et al. (October 1, 2000). "Contribution of Femoral and Proximal Sciatic Nerve Branches to the Sensory Innervation of Hindlimb Digits in the Rat," <i>The Anatomical Record</i> 260(2):180-188.
	/	120.	Rader, C. et al. (2001). "Antibody Engineering" Chapter 13 In Phage Display, A Laboratory Manual, Barbas III, C.F. et al. eds., Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, pp. 13.1-13.15.
J.	L	121.	Rinat Neurosciences. (Date Unknown). "RN624 A New Approach to Pain Therapy," located at http://64.233.161.104/search?q=cache:nYXEK1HDbdlJ:www.rinatneuro.com/products/RN6 , last visited July 5, 2006, five pages.

Examiner		Date	
	/Jon Lockard/		01/04/2007
Signature	/ CON DOCKGEG/	Considered	01/04/2007
40044	H-2		

٠١	estitute for form 1449/PTO			Complete if Known		
Sui	Stitute for form 1449/PTO	'		Application Number	10/682,332	
IN	NFORMATIO	N DI	SCLOSURE	Filing Date	October 8, 2003	
	TATEMENT			First Named Inventor	David L. SHELTON	
Ĭ			AI I EIOAII	Art Unit	1647	
	(Use as many sheets as necessary)			Examiner Name	J. Lockard	
Sheet	6	of	7	Attorney Docket Number	514712000600	

	122.	Rosok, M.J. et al. (September 13, 1996). "A Combinatorial Library Strategy for the Rapid						
JL		Humanization of Anticarcinoma BR96 Fab," The Journal of Biological Chemistry 271(37):22611-22618.						
	123.	Rudikoff, S. et al. (March 1982). "Single Amino Acid Substitution Altering Antigen-Binding Specificity," <i>Proc. Natl. Acad. Sci. USA</i> 79:1979-1983.						
	124.	Sabino, M.A.C. et al. (December 15, 2002). "Simultaneous Reduction in Cancer Pain, Bone Destruction, and Tumor Growth by Selective Inhibition of Cyclooxygenase-2," Cancer Res. 62:7343-7349.						
	125.	Sabino, M.A.C. et al. (May 1, 2003). "Different Tumors in Bone Each Give Rise to a Distinct Pattern of Skeletal Destruction, Bone Cancer-Related Pain Behaviors and Neurochemical Changes in the Central Nervous System," <i>International Journal of Cancer</i> 104(5):550-558.						
	126.	Safieh-Garabedian, B. et al. (August 1995). "Contribution of Interleukin-1β to the Inflammation-Induced Increase in Nerve Growth Factor Levels and Inflammatory Hyperalgesia," <i>Br. J. Pharmacol.</i> 115(7):1265-1275.						
	127.							
	128.	Shelton, D.L. et al. (December 1984). "Expression of the β-nerve Growth Factor Gene Correlates with the Density of Sympathetic Innervation in Effector Organs," <i>Proc. Natl. Acad. Sci. USA</i> 81:7951-7955.						
	129.	Shelton, D.L. et al. (1995). "Neurotrophins and Neurotrophin Antagonists as Potential Therapeutics," Restorative Neurology and Neuroscience 8(1-2):99-100.						
	130.	Shu, X. et al. (1999). "Nerve Growth Factor Acutely Sensitizes the Response of Adult Rat Sensory Neurons to Capsaicin," <i>Neurosci. Lett.</i> 274(3):159-162.						
	131.	Stedman, T.L. (1982). <u>Illustrated Stedman's Medical Dictionary</u> , Williams & Wilkins: Baltimore, MD, 24th Edition, pg. 670.						
	132.	Sunshine, A. et al. (1983). "Oral Analgesic Efficacy of Suprofen Compared to Aspirin, Aspirin plus Codeine, and Placebo in Patients with Postoperative Dental Pain," <i>Pharmacology</i> 27(Suppl.1):31-40.						
	133.	Szekanecz, Z. et al. (June 2000). "Temporal Expression of Inflammatory Cytokines and Chemokines in Rat Adjuvant-Induced Arthritis," <i>Arthritis & Rheumatism</i> 43(6):1266-1277.						
	134.	Tang, Y. et al. (September 24, 1999). "Use of a Peptide Mimotope to Guide the Humanization of MRK-16, an Anti-P-Glycoprotein Monoclonal Antibody," <i>The Journal of Biological Chemistry</i> 274(39):27371-27378.						
	135.	Thompson, J.E. et al. (1999). "A Fully Human Antibody Neutralising Biologically Active Human TGFβ2 for use in Therapy," J. Immunol. Methods 227:17-29.						
	136.	Tofaris, G.K. et al. (August 1, 2002). "Denervated Schwann Cells Attract Macrophages by Secretion of Leukemia Inhibitory Factor (LIF) and Monocyte Chemoattractant Protein-1 in a Process Regulated by Interleukin-6 and LIF," <i>J. Neurosci.</i> 22(15):6696-6703.						
	137.	Tsujino, H. et al. (February 2000). "Activating Transcription Factor 3 (ATF3) Induction by Axotomy in Sensory and Motoneurons: A Novel Neuronal Marker of Nerve Injury," <i>Molecular & Cellular Neuroscience</i> 15(2):170-182.						
	138.	Vajdos, F.F. et al. (2002), "Comprehensive Functional Maps of the Antigen-Binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis," <i>J. Mol. Biol.</i> 320:415-428.						
	139.	Vanderah, T.W. et al. (2001). "Mechanisms of Opioid-Induced Pain and Antinociceptive Tolerance: Descending Facilitation and Spinal Dynorphin," <i>Pain</i> 92:5-9.						
	140.	Vigneti, E. et al. (1993). "Production and Characterization of a Monoclonal Antibody Against Nerve Growth Factor (NGF) Which Recognizes Rodent and Human NGF," Year Immunol. 7:146-149.						
ΊĽ	141.	Villanueva, L. (December 2000). "Is There a Gap Between Preclinical and Clinical Studies of Analgesia?" <i>Trends Pharmacol. Sci.</i> 21(12):461-465.						

	والمراجع والمتعارض والمتعا	the second se	
Examiner	/ 1 1/	Date	
	/Jon Lockard/		01/04/2007
Signature	,	Considered	01/04/2007

Cub	stitute for form 1449/PT	٥.		Complete if Known		
Sub	Strute for form 1449/PT	0.		Application Number	10/682,332	
IN	INFORMATION DISCLOSURE			Filing Date	October 8, 2003	
	TATEMENT			First Named Inventor	David L. SHELTON	
	TATEMENT	ם יא	LIOAII	Art Unit	1647	
(Use as many sheets as necessary)			ecessary)	Examiner Name	J. Lockard	
Sheet	7	of	7	Attorney Docket Number	514712000600	

Complex with the Ligand-Binding Domain of the TrkA Receptor," Nature 401(6749):1		Wiesmann, C. et al. (September 9, 1999). "Crystal Structure of Nerve Growth Factor in Complex with the Ligand-Binding Domain of the TrkA Receptor," <i>Nature</i> 401(6749):184-188.	
		143.	Winter, C.A. et al. (June 1966). "Treatment of Adjuvant Arthritis in Rats with Anti-inflammatory Drugs," <i>Arthritis Rheum.</i> 9(3):394-404.
	144. Woolf, C.J. et al. (1994). "Nerve Growth Factor Contributes to the Generation of Inflammator Sensory Hypersensitivity," Neuroscience 62(2):327-331.		
	145. Wu, H. et al. (November 19, 1999). "Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues," J. Mol. Biol. 294(1):151-162.		
		146.	Wu, S.M. et al. (1998). "Oxidized α ₂ -Macroglobulin (α ₂ M) Differentially Regulates Receptor Binding by Cytokines/Growth Factors: Implications for Tissue Injury and Repair Mechanisms in Inflammation," <i>The Journal of Immunology</i> 161:4356-4365.
	•	147.	Wu, Z. et al. (December 2000). "Immunohistochemical Study of NGF and its Receptors in the Synovial Membrane of the Ankle Joint of Adjuvant-Induced Arthritic Rats," <i>Histochem. Cell Biol.</i> 114(6):453-459.
			Yelton, D.E. et al. (1995). "Affinity Maturation of the BR96 Anti-Carcinoma Antibody by Codon-Based Mutagenesis," The Journal of Immunology 155:1994-2004.
٠	149. Yu, Y.C. et al. (2002). "Two Variables That can be Used as Pain Indices in Experimental		Yu, Y.C. et al. (2002). "Two Variables That can be Used as Pain Indices in Experimental Animal Models of Arthritis," <i>Journal of Neuroscience Methods</i> 115:107-113.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner		Date
Signature	/Jon Lockard/	Considered 01/04/2007